ATE203666T1 - Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung - Google Patents

Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung

Info

Publication number
ATE203666T1
ATE203666T1 AT96108497T AT96108497T ATE203666T1 AT E203666 T1 ATE203666 T1 AT E203666T1 AT 96108497 T AT96108497 T AT 96108497T AT 96108497 T AT96108497 T AT 96108497T AT E203666 T1 ATE203666 T1 AT E203666T1
Authority
AT
Austria
Prior art keywords
antagonist
eye
muscarino
medication
regulation
Prior art date
Application number
AT96108497T
Other languages
English (en)
Inventor
Alan M Laties
Richard A Stone
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/522,241 external-priority patent/US5122522A/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE203666T1 publication Critical patent/ATE203666T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96108497T 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung ATE203666T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development

Publications (1)

Publication Number Publication Date
ATE203666T1 true ATE203666T1 (de) 2001-08-15

Family

ID=27004525

Family Applications (3)

Application Number Title Priority Date Filing Date
AT90911118T ATE147626T1 (de) 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
AT96108497T ATE203666T1 (de) 1989-06-21 1990-06-14 Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
AT94112616T ATE183085T1 (de) 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90911118T ATE147626T1 (de) 1989-06-21 1990-06-14 Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94112616T ATE183085T1 (de) 1989-06-21 1990-06-14 Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten

Country Status (9)

Country Link
US (2) US5356892A (de)
EP (1) EP0478694B1 (de)
JP (4) JP3165436B2 (de)
AT (3) ATE147626T1 (de)
CA (1) CA2058768C (de)
DE (3) DE69033775T2 (de)
DK (1) DK0737475T3 (de)
ES (2) ES2159661T3 (de)
WO (1) WO1990015604A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ATE147626T1 (de) * 1989-06-21 1997-02-15 Univ Pennsylvania Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
RU2002120485A (ru) * 2000-01-18 2004-04-10 Волли Фордж Фармасьютикл, Инк. (Us) Глазной рост и никотиновые антагонисты
EP1397132A4 (de) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I Ophthalmisches pirenzepin-gel
ITUB20160876A1 (it) 2016-02-19 2017-08-19 Dambrosio Enzo Maria Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
ATE147626T1 (de) * 1989-06-21 1997-02-15 Univ Pennsylvania Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
EP0478694A1 (de) 1992-04-08
DE69033246T2 (de) 1999-12-02
HK1007681A1 (en) 1999-04-23
CA2058768A1 (en) 1990-12-22
ATE147626T1 (de) 1997-02-15
US5356892A (en) 1994-10-18
EP0478694A4 (en) 1992-07-29
ATE183085T1 (de) 1999-08-15
DE69033246D1 (de) 1999-09-16
ES2136686T3 (es) 1999-12-01
CA2058768C (en) 2004-08-03
DE69033775D1 (de) 2001-09-06
JP3165436B2 (ja) 2001-05-14
ES2159661T3 (es) 2001-10-16
US5637604A (en) 1997-06-10
DE69029734T2 (de) 1997-05-28
JP3461778B2 (ja) 2003-10-27
DE69029734D1 (de) 1997-02-27
JPH05500502A (ja) 1993-02-04
EP0478694B1 (de) 1997-01-15
JP2004075695A (ja) 2004-03-11
WO1990015604A1 (en) 1990-12-27
JP2001081046A (ja) 2001-03-27
DE69033775T2 (de) 2001-11-15
DK0737475T3 (da) 2001-10-08
JP2000204049A (ja) 2000-07-25

Similar Documents

Publication Publication Date Title
DE69911620T2 (de) Muskarinische antagonisten zur behandlung von presbyopie
Fielding et al. A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions.
Pei A review of pharmacology and clinical use of piperine and its derivatives
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE203666T1 (de) Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung
BR9808254A (pt) Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.
ATE100322T1 (de) Verwendung von uridin zur behandlung nervoeser stoerungen.
KR920702622A (ko) 안구 발육의 치료 및 조절
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
Edwards et al. Catecholaminergic and cholinergic agents and duration regulation of ICSS in the rat
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
CA2454544A1 (en) Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient
BÄRÄNY Pilocarpine‐induced subsensitivity to carbachol and pilocarpine of ciliary muscle in vervet and cynomolgus monkeys
EP0919244A2 (de) Kombinationspräparate für die Therapie von Tumoren
Humphrey The relation of oxygen deprivation to fetal reflex arcs and the development of fetal behavior
DE69708084T2 (de) Verwendung von pyridyl- und pyrimidyl-piperazinen zur herstellung eines medikaments zur behandlung von rauschgiftsbedingten beschwerden
Share et al. R-enantiomer of timolol: a potential selective ocular antihypertensive agent
DE69027577T2 (de) Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen
Kimoto et al. Actions of the alpha-1 adrenoceptor blocker bunazosin on the norepinephrine-induced contraction of smooth muscles in the rabbit proximal urethra.
CA2369054A1 (en) Treatment and control of ocular development
Koss Analysis of pupillary dilation produced by analogs of clonidine
Leopold Trends in Ocular Therapy: The 23rd Sanford S. Gifford Memorial Lecture
HEY et al. Atypical α-adrenoceptor mediates phenylephrine-induced mydriasis in anesthetized cats
Dunagan et al. Nerves originating from the cerebral ganglion of Moniliformis moniliformis (Acanthocephala)
Dickinson et al. Effects of idazoxan on 5-hydroxytryptamine-mediated behaviour in the mouse and rat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee